Last update April 16, 2024



Safe substance and/or breastfeeding is the best option.

Perindopril and its active metabolite perindoprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure. Oral administration every 12-24 hours.

It is excreted in breastmilk in clinically insignificant amounts. (Leggett 2020, Anderson 2018, Lwin 2017)

Until more published data on this drug in relation to breastfeeding are known, safer alternatives with shorter elimination times may be preferable. 

Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)

The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)


  • Captopril (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Perindopril is also known as

Perindopril in other languages or writings:


Main tradenames from several countries containing Perindopril in its composition:


Variable Value Unit
Oral Bioavail. 65 - 75 %
Molecular weight 369 daltons
Protein Binding 20 - 60 %
VD 0.22 l/Kg
pKa 3.79 -
Tmax 3 - 4 hours
30 - 120 hours
M/P ratio 0.22 -
Theoretical Dose 0.00005 - 0.002 mg/Kg/d
Relative Dose 0.2 - 4.6 %


  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  3. Leggett C, Lwin EMP, Ritchie U, Song Y, Gerber JP, Turner S, Hague WM, Stark M, Upton R, Garg S. Perindopril in Breast Milk and Determination of Breastfed Infant Exposure: A Prospective Observational Study. Drug Des Devel Ther. 2020 Mar 2;14:961-967. Abstract Full text (link to original source)
  4. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  5. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  6. Lwin EMP, Gerber C, Song Y, Leggett C, Ritchie U, Turner S, Garg S. A new LC-MS/MS bioanalytical method for perindopril and perindoprilat in human plasma and milk. Anal Bioanal Chem. 2017 Abstract
  7. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  8. AEMPS. Perindopril Ficha técnica. 2012 Full text (in our servers)
  9. FDA. Perindopril. Drug Summary. 2011 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM